459 related articles for article (PubMed ID: 8996195)
1. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
Rush CR; Madakasira S; Goldman NH; Woolverton WL; Rowlett JK
J Pharmacol Exp Ther; 1997 Jan; 280(1):174-88. PubMed ID: 8996195
[TBL] [Abstract][Full Text] [Related]
2. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats.
Rowlett JK; Woolverton WL
J Pharmacol Exp Ther; 1997 Jan; 280(1):162-73. PubMed ID: 8996194
[TBL] [Abstract][Full Text] [Related]
3. Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans.
Rush CR; Baker RW; Rowlett JK
Exp Clin Psychopharmacol; 2000 Feb; 8(1):22-36. PubMed ID: 10743902
[TBL] [Abstract][Full Text] [Related]
4. Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics.
Rowlett JK; Spealman RD; Lelas S
J Pharmacol Exp Ther; 1999 Dec; 291(3):1233-41. PubMed ID: 10565847
[TBL] [Abstract][Full Text] [Related]
5. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal.
Griffiths RR; Sannerud CA; Ator NA; Brady JV
J Pharmacol Exp Ther; 1992 Mar; 260(3):1199-208. PubMed ID: 1312162
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus effects of benzodiazepine agonists and partial agonists in pentobarbital-trained rhesus monkeys.
Rowlett JK; Woolverton WL
Behav Pharmacol; 1998 Mar; 9(2):81-92. PubMed ID: 10065928
[TBL] [Abstract][Full Text] [Related]
7. Functional antagonism of the caffeine-discriminative stimulus by triazolam in humans.
Oliveto AH; Bickel WK; Hughes JR; Higgins ST; Badger G
Behav Pharmacol; 1997 Jun; 8(2-3):124-38. PubMed ID: 9833008
[TBL] [Abstract][Full Text] [Related]
8. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports.
Oliveto AH; Bickel WK; Hughes JR; Shea PJ; Higgins ST; Fenwick JW
J Pharmacol Exp Ther; 1992 Jun; 261(3):885-94. PubMed ID: 1602393
[TBL] [Abstract][Full Text] [Related]
9. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
Evans SM; Funderburk FR; Griffiths RR
J Pharmacol Exp Ther; 1990 Dec; 255(3):1246-55. PubMed ID: 2262904
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans.
Oliveto AH; Rosen MI; Woods SW; Kosten TR
J Pharmacol Exp Ther; 1995 Jan; 272(1):231-41. PubMed ID: 7815337
[TBL] [Abstract][Full Text] [Related]
11. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans.
Stoops WW; Lile JA; Glaser PE; Rush CR
Exp Clin Psychopharmacol; 2005 Feb; 13(1):56-64. PubMed ID: 15727504
[TBL] [Abstract][Full Text] [Related]
12. Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons.
Ator NA
Psychopharmacology (Berl); 2002 Oct; 163(3-4):477-87. PubMed ID: 12373448
[TBL] [Abstract][Full Text] [Related]
13. Discriminative-stimulus effects of triazolam in light and moderate drinkers.
Rush CR; Kelly TH; Fillmore MT; Hays LR
Alcohol Clin Exp Res; 2003 Apr; 27(4):638-46. PubMed ID: 12711926
[TBL] [Abstract][Full Text] [Related]
14. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
Depoortere H; Zivkovic B; Lloyd KG; Sanger DJ; Perrault G; Langer SZ; Bartholini G
J Pharmacol Exp Ther; 1986 May; 237(2):649-58. PubMed ID: 2871178
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects.
Berlin I; Warot D; Hergueta T; Molinier P; Bagot C; Puech AJ
J Clin Psychopharmacol; 1993 Apr; 13(2):100-6. PubMed ID: 8463441
[TBL] [Abstract][Full Text] [Related]
16. Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure.
Mintzer MZ; Frey JM; Griffiths RR
Behav Pharmacol; 1998 Nov; 9(7):545-59. PubMed ID: 9862080
[TBL] [Abstract][Full Text] [Related]
17. Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics.
Ator NA; Griffiths RR
J Pharmacol Exp Ther; 1997 Sep; 282(3):1442-57. PubMed ID: 9316858
[TBL] [Abstract][Full Text] [Related]
18. Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo.
Smith BJ; Bickel WK
Drug Alcohol Depend; 2001 Feb; 61(3):249-60. PubMed ID: 11164689
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone.
Oliveto AH; Bickel WK; Hughes JR; Terry SY; Higgins ST; Badger GJ
Behav Pharmacol; 1993 Jun; 4(3):237-246. PubMed ID: 11224191
[TBL] [Abstract][Full Text] [Related]
20. Flumazenil discrimination by humans under a two-response and a novel-response procedure.
Smith BJ; Bickel WK
J Pharmacol Exp Ther; 1999 Dec; 291(3):1257-68. PubMed ID: 10565850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
